Table 1. The number of controls, RER-susceptible (no dantrolene) and RER mares treated with dantrolene (RER-D).
| N | Age | Time since last work | Post exercise AST (range) | Post exercise CK (range) | Type 1 | Type 2A | Type 2X | |
|---|---|---|---|---|---|---|---|---|
| yrs | Hours | U/L | U/L | % | % | % | ||
| Control | 5 | 3.0 ± 0.9 | 3.7 ± 1.3 | 359 ± 108 (263–537) | 240 ± 57 (172–342) | 12.6 ± 3.9 | 29.5 ± 14.4 | 58.0 ± 15.2 |
| RER-susceptible | 5 | 4.0 ± 1.5 | 2.2 ± 1.2 | 557 ± 305 (219–921) | 349 ± 207 (131–663) | 9.0 ± 2.2 | 36.6 ± 4.9 | 54.4 ± 5.5 |
| RER-D | 5 | 3.6 ± 0.8 | 3.1 ± 1.6 | 568 ± 191 (254–840) | 941 ± 828 (200–2445) | 10.1 ± 2.2 | 34.7 ± 10.6 | 55.2 ± 11.7 |
| P value | 0.48 | 0.33 | 0.33 | 0.14 | 0.18 | 0.61 | 0.89 |
The mean (SD) age, sex, time lapse between exercise and muscle biopsy, plasma aspartate transaminase (AST) and creatine kinase (CK) activities at time of biopsy, and percentage of gluteal muscle type 1, 2A and 2X fibers are shown. There were no significant differences in any parameters between control, RER-susceptible and RER-D horses.